Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China

Introduction: The substantial financial burden associated with type 2 diabetes (T2D) over a lifetime cannot be neglected. Therefore, the objective of this study was to evaluate the pharmacoeconomic value of three once-weekly GLP-1 RAs, namely subcutaneous semaglutide (sc. SEMA), dulaglutide (DULA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Shanshan, Wang, Shuowen, Qi, Chendong, Gu, Shengying, Shi, Chenyang, Mao, Lin, Fan, Guorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894868/
https://www.ncbi.nlm.nih.gov/pubmed/35250578
http://dx.doi.org/10.3389/fphar.2022.831364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894868/
https://www.ncbi.nlm.nih.gov/pubmed/35250578
http://dx.doi.org/10.3389/fphar.2022.831364

Ejemplares similares